how do i tell if it s benign pvc s or arvc
play

How do I tell if its benign PVCs or ARVC? Robert M. Hamilton The - PowerPoint PPT Presentation

How do I tell if its benign PVCs or ARVC? Robert M. Hamilton The Hospital for Sick Children & Research Institute Autopsy from Ten Year Old Female following Sudden Cardiac Death Why differentiate RVOT VT/PVCs from A(RV)C? }


  1. How do I tell if it’s benign PVC’s or ARVC? Robert M. Hamilton The Hospital for Sick Children & Research Institute

  2.  Autopsy from Ten Year Old Female following Sudden Cardiac Death

  3. Why differentiate RVOT VT/PVC’s from A(RV)C? } 25%  RVOT VT is relatively benign  ARVC is a progressive disease and a significant cause of sudden cardiac death.  Even in Children!  Tabib, 2003  DuPuis, 2005  Pilmer, 2014

  4. Right Ventricular Outflow Tract VT(PVC’s)  Monomorphic VT originating from RVOT  Usually no underlying structural heart disease  May also occur in the context of ARVC  Heart rate > 100 bpm.  QRS duration > 120 ms.  LBBB Morphology  Rightward / inferior axis (around +90 degree)  ± VA dissociation.

  5. Right Ventricular Outflow Tract VT  Two predominant forms (Lerman et al, 1996)  repetitive monomorphic nonsustaincd VT  paroxysmal exercise induced sustained VT

  6.  48 Children with RVOT VT (5 Centers)  8.2 yrs (0.1-17.0 yrs); F/U 22 mo. (1-210 mo.)  82% referred for incidental finding, but 46% reported symptoms to cardiologist  15% referred for syncope or near-syncope  40% had a history of exercise intolerance  10% had a family history of arrhythmia

  7.  MRI performed in 25 (52%)  abnormalities in 13 (wall thinning in 8, fatty infiltration in 4, fibrosis in 2, and dyskinesia in 2)  Biopsies performed in 12 (25%)  Minor changes in 5 (fibrosis, interstitial lymphocyte infiltration, interstitial edema, and mild hypertrophy)  Catheterization performed in 11 (23%)  findings included focal dyskinesia in 1, apical hypokinesia in 1 & segmental wall-motion abn. in 1 Some may have had early ARVC, but no deaths occurred

  8.  Derivation Cohort: 16 ARVD/C v. 42 RVOT-VT  Validation Cohort: 37 ARVD/C v. 49 RVOT-VT  ARVD/C met task force criteria  RVOT-VT Structurally Nl, Successfully Ablated

  9.  No difference in Sx or Exercise-related Sx  FH in 60% of ARVC, 0% of RVOTO-VT  Abn ECG in 52% of ARVC. T-inv. In 36%  Abn SAECG in 78% of ARVC, NoRVOTO-VT  All RVOT-VT and 53% of ARVC: inf. axis VT  42% of ARVC had 2+ morphologies of VT  PES ind. VT in ARVC, Isuprel in RVOT-VT  Fragmented Potentials v. Presystolic Potentials

  10.  Compared LBBB-Inf. Axis Arrhythmias between ARVC and RVOT-VT  Follow-up not stated  ARVC had:  Longer mean QRSdd (150 ± 31 v. 123 ± 34 ms)  Precordial transition in V6 (3/17 v. 0//42)  Notching in 1+ lead (11/17 v. 9/42)

  11. Differentiating RVOT VT from ARVC Feature RVOT VT ARVC Mechanism Unifocal LBBB Nl Axis Re-entry (slow conduction) PVC’s Unifocal LBBB Nl Axis Multifocal LBBB VT Repetitive MMVT+/or Stress-related MMVT Paroxysmal Ex.-ind. QRS Normal +/- prolonged S duration in V1 Normal +/- prolonged SAECG Normal +/- prolonged MRI Normal +/- RV dil & dysk T-wave altenans Negative +/- positive Ablation Success in 94% Var. success and recurrence Family History VT/SCD Negative Often Positive Genetic basis Somatic mutation in Desmosomal in 1/3

  12. General observations  Understanding PVC’s is complex. They are capricious. Often can’t find out why they come, leave, come back.  Response to exercise helpful but not absolute (Gross)  PVC’s are defined by the company they keep (Usially benign if isolated and heart is structurally and functionally normal)  Freq. PVC’s or isolated RVOT VT = a single minor Task Force criterion (ARVC unlikely)

  13. My Approach  Take a family history!  Asymptomatic PVC’s  Assess morphology: RVOT vs. LV vs. RV body  ECG, Holter , SAECG (≥5), Ex. Test (≥6), Echo  Consider 12-lead Holter, ? T-wave alternans  Not RVOT morphology, multiple morphologies or abn SAECG or Echo: MRI (≥9)  Minimally symptomatic (palpitations)  Non-invasive monitors  Symptomatic (syncope: non-vasodepressor)  MRI, genetics, ± EP study, ILR  ?ARVC: Genetics, biomarker in development

  14. Master Thesis Sarah Vermij Q (Toon van Veen) U June 2014 E S T I O N S ? robert.hamilton@sickkids.ca

Recommend


More recommend